Opinion statement
Major therapeutic advances have occurred over the last several years in the management of advanced ALK+ NSCLC patients. Crizotinib was the first agent approved for the management of ALK+ NSCLC patients after it demonstrated significantly greater clinical benefit compared to chemotherapy. Several next generation ALK inhibitors have demonstrated clinical benefit in patients with crizotinib refractory NSCLC patients including in the CNS. Based on available data, therapy with a next generation ALK inhibitor can be initiated following therapy with crizotinib without any assessment of the molecular mechanisms of resistance. The appropriate therapy for patients with progressive disease following two ALK inhibitors is not well defined. In patients with an ALK-resistant mutation in their tumor, an ALK inhibitor with activity against the mutation would be the most appropriate therapy. In others, chemotherapy and PD-1 directed agents can be considered. Clinical data suggests that ALK+ patients are less likely to benefit from PD-1 directed agents and therefore chemotherapy should be considered prior to these agents for the management of ALK+ NSCLC patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References and Recommended Reading
Papers of particular interest, published recently, have been highlighted as: •• Of major importance
•• Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer. Nature. 2007;448:561–6. First manuscript to identify ALK translocation as a driver genetic alteration in NSCLC.
Shaw AT, Engelman JA. ALK in lung cancer: past, present and future. J Clin Oncol. 2013;31:1105–11.
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.
Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small cell lung cancer: updated results from a phase I study. Lancet Oncol. 2012;13:1011–9.
Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.
•• Solomon BJ, Mok T, Kim DW, et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014;371:2167–77. First study to demonstrate that an ALK inhibitor provides greater clinical benefit than a platinum based chemotherapy combination.
Yoshida T, Oya Y, Tanaka K, et al. Differential crizotinib response duration among ALK fusion variants in ALK-positive non-small-cell lung cancer. J Clin Oncol. 2016;34:3383–9.
•• Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumors: learning from lung cancer. Nat Rev Clin Oncol. 2014;11:473–81. Provides a comprehensive review of mechanisms of resistance to tyrosine kinase inhibitors.
Katayama R, Shaw AT, Khan TM, et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med. 2012;4:120ra17.
Doebele R, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012;18:1472–82.
•• Costa DB, Shaw AT, Ou SH, et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases. J Clin Oncol. 2015;33:1881–8. Data from crizotinib trials that highlights the frequent occurrence of brain recurrence in patients treated with crizotinib.
Costa DB, Kobayashi S, Pandya SS, et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol. 2011;29:e443–5.
Zhang S, Anjum R, Squillace R, et al. The potent ALK inhibitor brigatinib (AP26113) overcomes mechanisms of resistance to first- and second-generation ALK inhibitors in preclinical models. Clin Cancer Res. 2016;22:5527–38.
Gainor JF, Dardaei L, Yoda S, et al. Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov. 2016;6:1118–33.
Kim DW, Mehra R, Tan DS, et al. Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicenter open-label phase trial. Lancet Oncol. 2016;17:452–63.
Ou SH, Ahn JS, De Petris L, et al. Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol. 2016;34:661–8.
Camidge DR, Tiseo M, Ahn MJ, et al. Brigatinib in crizotinib-refractory ALK+ NSCLC: central assessment and updates from ALTA, a pivotal randomized phase 2 trial. J Thorac Oncol. 2017;12:S1. S612, abstract P3.02A-013
Horn L, Wakelee H, Reckamp K, et al. Response and plasma genotyping from phase I/II trial of ensartinib (X-396) in patients with ALK+ NSCLC. J Thorac Oncol. 2017;12:S1159. abstract P3.02a-001
Scagliotti G, Kim T, Crino L, et al. Ceritinib vs chemotherapy in patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer (NSCLC) previously treated with CT and crizotinib: Results from the confirmatory phase 3 ASCEND-5 study. Ann Oncol 2016; 27:Suppl 6:abstract LBA42_PR.
Solomon BJ, Bauer TM, Felip E, et al. Safety and efficacy of lorlatinib (PF-06463922) from the dose-escalation component of a study in patients with advanced ALK+ or ROS+ non-small cell lung cancer. J Clin Oncol 2016; 34:suppl;abstract 9009.
•• Nokihara H, Hida T, Kondo M, et al. Alectinib versus crizotinib in ALK-inhibitor naïve ALK-positive non-small cell lung cancer: Primary results from the J-ALEX study. J Clin Oncol 2016; 34:suppl, abstract 9008. First study to compare two ALK inhibitors in patients with advanced ALK+ NSCLC patients.
Castro DG, Tan DS, Crino L, et al. First-line ceritinib versus chemotherapy in patients with ALK-rearranged NSCLC. A randomized phase 3 study (ASCEND-4). J Thorac Oncol. 2016;12:S1. page S4, abstract PL03.07
Soria JC, Wu YL, Nakagawa K, et al. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomized trial. Lancet Oncol. 2015;16:990–8.
Gainor J, Shaw AT, Sequist LV, et al. EGFR mutations and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer: a retrospective analysis. Clin Cancer Res. 2016;22:4585–93.
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348:124–8.
Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-10): a randomized controlled trial. Lancet. 2016;387:1540–50.
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicenter randomized controlled trial. Lancet 2016;389:255-65.
Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1 positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33.
Khan AJ, Mehta PS, Zusag TW, et al. Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiother Oncol. 2006;81:163–7.
Sheu T, Heymach J, Swisher SG, et al. Propensity score-matched analysis of comprehensive local therapy for oligometastatic non-small cell lung cancer that did not progress after front line chemotherapy. Int J Radiat Oncol Biol Phy. 2014;90:850–7.
Weickhardt AJ, Scheier B, Burke JM, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807–14.
Gomez DR, Blumenschein GR, Lee J, et al. Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicenter, randomized, controlled, phase 2 study. Lancet Oncol. 2016;17:1672–82.
Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to selected targeted drugs. JAMA. 2016;311:1998–2006.
Katayama R, Lovly CM, Shaw AT. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine. Clin Cancer Res. 2015;21:2227–35.
Gettinger S, Politi K. PD-1 axis inhibitors in EGFR- and ALK- driven lung cancer: lost cause? Clin Cancer Res. 2016;22:4539–41.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Shirish M. Gadgeel has received compensation from Roche/Genentech, Pfizer, Bristol-Myers Squibb, ARIAD, and Boehringer Ingelheim for serving on advisory boards, and from AstraZeneca for both serving on an advisory board and as a guest speaker.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Additional information
This article is part of the Topical Collection on Lung Cancer
Rights and permissions
About this article
Cite this article
Gadgeel, S.M. Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. Curr. Treat. Options in Oncol. 18, 36 (2017). https://doi.org/10.1007/s11864-017-0479-8
Published:
DOI: https://doi.org/10.1007/s11864-017-0479-8